Adult cancers may derive from stem or early progenitor cells 1,2 . Epigenetic modulation of gene expression is essential for normal function of these early cells but is highly abnormal in cancers, which often show aberrant promoter CpG island hypermethylation and transcriptional silencing of tumor suppressor genes and pro-differentiation factors 3-5 . We find that for such genes, both normal and malignant embryonic cells generally lack the hypermethylation of DNA found in adult cancers. In embryonic stem cells, these genes are held in a 'transcription-ready' state mediated by a 'bivalent' promoter chromatin pattern consisting of the repressive mark, histone H3 methylated at Lys27 (H3K27) by Polycomb group proteins, plus the active mark, methylated H3K4. However, embryonic carcinoma cells add two key repressive marks, dimethylated H3K9 and trimethylated H3K9, both associated with DNA hypermethylation in adult cancers 6-8 . We hypothesize that cell chromatin patterns and transient silencing of these important regulatory genes in stem or progenitor cells may leave these genes vulnerable to aberrant DNA hypermethylation and heritable gene silencing during tumor initiation and progression.
Epigenetic gene silencing and associated promoter CpG island DNA hypermethylation are prevalent in all cancer types and are an alternative mechanism to mutations that inactivate tumor suppressor genes within a cancer cell [3] [4] [5] . These epigenetic changes may precede genetic changes in premalignant cells and foster the accumulation of additional genetic and epigenetic hits 9 . Adult cancers may derive from stem or early progenitor cells 1, 2 , and epigenetic modulation of gene expression is essential for the normal functioning of these early cells. We now explore whether DNA hypermethylation and heritable silencing of groups of genes in adult tumor initiation and progression might reflect chromatin properties of these genes associated with stem or precursor cells.
We compared the epigenetic status of a group of genes frequently hypermethylated and silenced in adult cancers ( Fig. 1 ; associated references listed in Supplementary Table 1 online) in both normal embryonic stem (ES) cells and malignant counterparts of these cells, embryonal carcinoma (EC) cells 10 . Notably, we found that the genes frequently undergoing promoter CpG island DNA hypermethylation in adult human cancer cells generally remained unmethylated in both ES and EC cells (Fig. 1) . Among the genes studied, 13 of 29 (45%) were hypermethylated in a single adult colon cancer line, HCT-116, but none was hypermethylated in ES cells, and only 3% and 7% were completely methylated in the Tera-1 and Tera-2 EC lines, respectively. Thus, the key epigenetic parameter of promoter CpG island hypermethylation, which is common in a large group of genes in adult cancer cells, does not seem to be a common feature of EC cells.
In mouse ES cells, many developmental genes are maintained in a state of low transcriptional activity and are available for transcriptional increases or decreases when differentiation cues are received 11 . The genes we studied in EC cells retained this plasticity of expression, which is lacking in adult cancers when these same genes are hypermethylated. Both ES and EC cells can be induced to differentiate toward a neural lineage with all-trans retinoic acid (ATRA) in vitro 10 . The genes we studied with a high basal transcription state in EC cells (Fig. 2a) generally showed lower expression after ATRA treatment. However, a second, larger cluster of genes showed low to medium expression in undifferentiated Tera-2 cells (Fig. 2a) , and the majority of these (9 of 11) showed a distinct activation pattern with increased expression upon or during differentiation (Fig. 2a) .
Both ES and EC cells, when grown as xenografts in NOD/SCID mice, form teratomas and teratocarcinomas, respectively, in which there is spontaneous differentiation and multilineage commitment to varying degrees 10 (Fig. 2b) . The changes in expression of the genes we studied in these tumors were similar to the changes induced by ATRA in EC cells ( Fig. 2c; for example, see CDKN2A (also known as p16), GATA4 and GATA5). E-cadherin and SFRP5 are notable exceptions, and differences probably reflect multilineage commitment in vivo versus single-lineage differentiation in vitro.
We found that the promoter regions of the genes we studied each contained a combination of active (dimethylated H3K4) and repressive (trimethylated H3K27) histone modifications in ES cells (Fig. 3a) . This 'bivalent' state has been recently described in mouse ES cells 11, 12 for a subset of developmental genes that are maintained in a low expression state; here, we extend these observations to genes frequently epigenetically silenced in cancer. We have previously found trimethylated H3K27 to be enriched at each of the of the promoters of a small panel of DNA-hypermethylated genes we studied in adult cancer cells 6 . This histone modification is catalyzed by EZH2, a key component of the Polycomb group (PcG) complexes (PRC1, PRC2/3 and PRC4) (Fig. 3b) that maintain long-term gene silencing in diverse organisms and are essential for the normal state of stem and progenitor cells and their commitment to various tissue types 13, 14 . Recent studies have linked EZH2 with DNA methyltransferases and have established a role for this protein during the induction and targeting of DNA methylation 15 . These complexes are present in stem and progenitor cells as well as in tumor cells that have similar properties 14, 16 .
We next matched our list of genes showing frequent DNA hypermethylation in adult cancers to the full list of PcG-targeted genes identified by recent studies of human and mouse ES 17, 18 and embryonic fibroblast (EF) cells 19 . These genome-wide tiling studies identified between ∼8% (PRC2; ES cells) 17 and ∼14% (PRC1/PRC2; EF cells) 19 of the annotated genome to be PcG regulated in these cell types. Notably, we found that 68% of the genes in Figure 1 were associated with PcG in either ES or EF cells, as were 56.5% of 23 genes (Fig. 3b) newly identified as hypermethylated in HCT-116 cells (K.E.S. et al., data not shown).
Among embryonic cells, the degree of lineage commitment may determine the balance of chromatin modifications at gene promoters and the genes' basal expression levels 11 . Similarly, this may be true for compartments of precursor cells in adult renewing cell systems from which adult cancers derive. We found it interesting that of the genes from Figure 1 that were identified as PcG targets, approximately 50% were listed as PcG targets in both ES and EF cells. However, the remaining 50% were listed as unique PcG targets in either ES or EF cells. This might explain how different patterns of hypermethylated genes in adult cancers might, then, reflect their chromatin status in cells from which cancers develop.
We found that although the genes studied in EC cells shared the bivalent chromatin pattern seen in ES cells (Fig. 4a,b) , they also acquired two additional key repressive marks characteristic of adult cancers in EC cells. Thus, trimethylated H3K9, which is characteristic of silenced transcription in pericentromeric regions 20 , and to a lesser and more variable extent, dimethylated H3K9, were enriched at the (Fig. 4a,c) . Both of these H3K9 marks are characteristic of DNA-hypermethylated genes in adult cancers 6 . In both Neurospora and Arabidopsis thaliana, mutations in genes encoding histone methyltransferases that catalyze H3K9 methylation cause significant loss of genomic DNA methylation [21] [22] [23] . We found it interesting that in the EC cells, global levels of both of the H3K9 repressive marks were considerably higher than in ES cells (Fig. 4d) , suggesting a permissive background for the promoter changes in the neoplastic cells. Although the chromatin pattern identified above in EC cells is similar to that for DNA-hypermethylated genes in adult cancers, several important differences exist. First, in adult cancer cells, the activating mark, methylated H3K4, is diminished, and these genes generally have fully repressive rather than bivalent chromatin 6, 24 . However, this activating mark is enriched again when expression and DNA demethylation of these genes in adult cancer cells are induced, either by genetic knockout of DNA methyltransferases or treatment with 5-aza-2′-deoxycytidine (DAC) 6, 24 . Second, in adult cancers, the repressive chromatin present for DNA-hypermethylated genes is initially more enriched for dimethylated H3K9 (refs. 6,24) than is seen in the EC cells. The ratio of trimethylated H3K9 to dimethylated H3K9 in EC for unmethylated genes is greater than 5:1 in Tera2 cells, compared with a mean of 1.2:1 (ref. 6) for DNA-hypermethylated promoters in adult cancers (Fig. 4d) . Notably, in EC cells, the fully methylated RASSF1 gene and the minimally methylated SFRP5 gene both demonstrated an increased presence of the dimethylated H3K9 mark at their promoters (Fig. 4a) . Most importantly, when DNA-hypermethylated genes are demethylated in adult cancer cells, dimethylated H3K9 is the only repressive mark uniformly reduced 6, 24 , and the ratio of trimethylated H3K9 to dimethylated H3K9 increases to 4:1 (see the mean for previously published results in Fig. 4d) , a value virtually identical to that for unmethylated genes in EC cells 6, 24 (Fig. 4d) .
The chromatin findings for genes in EC cells present an opportunity to study how the various repressive histone modifications and the proteins that maintain them are altered with differentiation of these cells. This is a key question, as DNA-hypermethylated genes in adult cancers are very deeply, heritably repressed and thus are difficult to reactivate unless the DNA methylation is removed. We first observed that the key PcG proteins SUZ12, EZH2 and SirT1 were enriched at the promoters of the genes in EC cells (Fig. 5a) . The steady-state levels of these proteins fell (Fig. 5b) , as did their levels at the above promoters, with ATRA treatment (Fig. 5c) . Additionally, several PcG proteins, including Bmi1, Suz12 and Sfmbt, showed a transient increase in expression at various points during the differentiation process, followed by a lowering of expression as cells entered a more differentiated state. These data support the extensive work of others in discerning a role for this family during normal differentiation 16 .
In mouse ES cells, many developmental genes marked by the above bivalent chromatin states are maintained in a low expression state but demonstrate a plasticity of chromatin and expression by increasing transcription and shifting to a more monovalent active chromatin pattern when differentiation cues are received 11 . We see this for CDKN2A (also known as p16) and GATA4, which have a moderate to low basal expression state in EC cells and an equivalent initial ratio of dimethylated H3K4 to trimethylated H3K27 (Fig. 4a,b) but adopt a more active, monovalent state as their expression is distinctly increased by ATRA (Fig. 5d) . A second subset of genes (CDH1, SFRP1 and SFRP2) showing frequent DNA hypermethylation in adult cancers and with a higher basal expression level in EC cells and a higher initial ratio of active to repressive marks (Fig. 4a,b) , generally showed lower expression after ATRA treatment (Fig. 2a) and showed a decrease in the ratio of dimethylated H3K4 to trimethylated H3K27 (Fig. 5d ). An exception is CDKN2B (also known as p15), which is expressed at an intermediate level in undifferentiated cells and demonstrates significant upregulation with differentiation ( Fig. 2a) but already shows an active, monovalent chromatin state in EC cells (Fig. 4a,b) that is not significantly altered with differentiation (Fig. 5d) .
If a stem cell gene promoter chromatin pattern, including PcGmediated repressive histone modifications, might help render certain genes vulnerable to DNA hypermethylation, can one perturb the system in embryonic cells to further test this hypothesis? We tested this by forcing overexpression of Bmi1, a central component of PRC1. PRC1 is involved in recognition of the H3K27 mark established by EZH2 in the PRC2 complex and has a role in subsequent maintenance of PcG-mediated long-term gene silencing 13, 14 . Bmi1 is endogenously expressed in the wild-type Tera2 cells and shows a transient increase and subsequent decline during ATRA-induced differentiation (Fig.  5b) . Forced, stable overexpression of Bmi1 in these cells resulted in an initial increase in BMI1 mRNA that was sustained for more than ten passages and then returned to baseline (Fig. 6a) . This was accompanied in pooled cells, and multiple cloned populations studied, by an overall increase in cell proliferation, cell number and loss of contact inhibition of subsets of cells in vitro that was seen only infrequently in wild-type cells (Fig. 6b) . The overexpression of Bmi1 did not acutely induce methylation of most unmethylated tumor-suppressor genes examined, including CDKN2A (also known as p16), E-cadherin, GATA4 or GATA5. However, in the pooled cells and in two of five separate clones studied, increased DNA methylation of the Wnt antagonist gene SFRP5 occurred over time (Fig. 6c) , a result never observed in wild-type cells over chronic passages. The histone modifications at the SFRP5 promoter remained unchanged in the pooled Bmi1-overexpressing cells through passage 10 (Fig. 6d) . However, as DNA methylation increased at passage 20 for one clone examined, the ratio of dimethylated H3K9 to trimethylated H3K9 became approximately equal (Fig. 6d) and thus was similar to that for DNA-hypermethylated genes in adult cancers 6 ( Fig. 4c) . In summary, our studies demonstrate that genes showing frequent DNA hypermethylation and deep transcriptional silencing in adult cancers usually lack such DNA methylation in normal and neoplastic embryonic cells. However, the chromatin of these genes is virtually identical in embryonic cancer cells to that of the genes in adult cancers, especially when the DNA methylation in the latter cells is reduced and the involved genes are re-expressed. The repressive pattern for the EC cells may, then, represent a 'transition' state somewhere between that for genes in ES cells and that for fully DNA-hypermethylated and tightly silenced genes in adult cancers that facilitate neoplastic progression. When DNA demethylation is transiently induced by drugs in DNA-hypermethylated genes in adult cancers, they retain a promoter chromatin pattern virtually identical to what we now show in EC cells; this may be important in explaining why these same genes reacquire the DNA methylation and silencing once the drug is removed 6, 25 .
In terms of human cancer biology, our findings suggest that a stem cell-like promoter 'ground state' involving the key PcG mark, trimethylated H3K27, may be indicative of the contribution of stem cell and/ or progenitor cells to the derivation of adult cancers ( Supplementary  Fig. 1 online) . We and others have suggested that stem and progenitor cells are especially at risk for cancer initiation owing to their continued expansion during states such as chronic wound healing and inflammation 9, 26 . If further repressive marks for H3K9 are added to the stem cell chromatin state described here, the combination of H3K27 and H3K9 methylation may provide a program for making key tumor suppressor genes vulnerable for imposition of promoter CpG island DNA methylation during such expansion (Supplementary Fig. 1 ). These changes may enhance the likelihood of tumor initiation and progression from cell transformation as it renders a transient 'transcription-ready' state to one of heritable, permanent gene silencing.
METHODS
Cell culture. Tera-1, Tera-2 and HCT-116 (ATCC) cells were maintained in McCoy's 5A medium supplemented with 10% FBS and grown at 37 °C under 5% CO 2 , as were HCT 116 cells in which both DNA methyltransferases 1 and 3b are genetically deleted (DKO cells) 27 . DNA for methylation-specific PCR (MSP) was isolated in the laboratory of S.J.S. (Johns Hopkins University) from the human ES cell line WA01 (WiCell Research Institute) according to established protocols. Cross-linking for human ES cell chromatin immunoprecipitation (ChIP) and subsequent DNA isolation was performed in the laboratory of L. Cheng (Johns Hopkins University) using the human ES cell lines WA01 and WA09 (WiCell Research Institute).
Bisulfite treatment and MSP. Bisulfite treatment and MSP were performed as described previously 28 . DNA was extracted following a standard phenol-chloroform
H3K9me3 H3K4me2 extraction method. Primer sequences and cycling conditions are included in Supplementary Table 2 online. Any information not included is available by request from the authors.
RNA purification and real-time RT-PCR analysis. RNA was isolated with TRIzol Reagent (Invitrogen) according to the manufacturer's instructions. For RT-PCR, 1 µg of total RNA was reverse transcribed using the Superscript First-Strand Synthesis System (Invitrogen). Quantitative real-time RT-PCR was performed as described previously 29 . PCR primers and amplification conditions are included in Supplementary Table 2 . Any information not included is available by request from the authors.
ChIP. ChIP assays were performed as described previously 6 , with the modification that immunoprecipitation was performed using Dynal Magnetic beads purchased from Invitrogen (Protein A beads (100-02D) and Protein G beads (100-04D)). Antibodies to trimethylated H3K27, dimethylated H3K9 and trimethylated H3K9 were produced as previously described 6 . Antibodies to Suz12 (Abcam); H3K4me2, EZH2 (Upstate) and SIRT1 (Delta Biolabs) were purchased from commercial sources. Primers and amplification conditions are included in Supplementary  Table 2 . Any information not included is available by request from the authors.
Lentiviral vector preparation, viral production and infection.
An untagged Bmi1 lentiviral expression clone was generated using the full-length cDNA from a pBABE-puro retroviral construct (see Acknowledgments) and using the ViraPower Promoterless Lentiviral Gateway System (Invitrogen). Briefly, a Bmi1 entry clone with an intact stop codon was incorporated along with a second UbC promotercontaining entry clone obtained with this kit (pENTR5′-UbCp) into the pLenti6/ R4R2/V5-DEST vector from Invitrogen. The expression clone was transformed into Stbl3-competent cells (Invitrogen), and Bmi1-containing recombinants were selected using ampicillin and blasticidin resistance and were confirmed by restriction digest. Plasmid DNA was purified using GenElute Plasmid Maxiprep Kit (SigmaAldrich), and lentivirus was packaged in 293FT cells and infected in Tera2 cells using the manufacturer's recommended protocols. Blasticidin (0.5-1 µg/ml) was added to complete medium 48 h post-infection, and stable expressing pools and clones were maintained in 0.5 µg/ml blasticidin for the duration of the experiments.
Note: Supplementary information is available on the Nature Genetics website.
